Pfizer-Allergan deal could reduce biosimilar cost savings

Pfizer-Allergan deal could reduce biosimilar cost savings

By Steven Ross Johnson  |  December 05, 2015

Pfizer's $160 billion deal to acquire Irish drugmaker Allergan got a lot of attention for the tax advantages Pfizer would enjoy from moving its New Jersey headquarters overseas to Dublin. There wasn't much talk, though, about how much the deal would expand Pfizer's footprint in biosimilars.

Data show Genentech paid the most to providers

By Art Golab and Michael Sandler  |  July 04, 2015

Genentech, the maker of Avastin and other pricey cancer drugs, paid physicians and teaching hospitals more than any other drug or device company did in 2014, according to data published last week on the CMS' Open Payments website.

Diabetic eye-drug study sheds light on efficacy vs. cost

By Andis Robeznieks  |  February 20, 2015

A comparative-effectiveness test of three popular drugs used to treat a common diabetic eye disorder found all three drugs improved eyesight among diabetics with mild vision loss, but the most expensive drug delivered the best outcomes among subjects with the worst vision.

340B hospitals protest Genentech's cancer-drug distribution plan

By Jaimy Lee  |  October 23, 2014

A group of hospitals that participate in the federal 340B drug-discount program have joined the debate about Genentech's decision to distribute three of its most expensive and commonly used cancer drugs through specialty distributors rather than standard wholesalers.

Consumers cheer wearables, but don't wear them, yet

Consumers cheer wearables, but don't wear them, yet

By Darius Tahir  |  October 21, 2014

Consumers are highly optimistic about wearable devices' potential to improve healthcare, even though most now are not using wearables to track their own health, PricewaterhouseCoopers Health Research Institute says in a new report.

Reform Update: Ascension Health bars Genentech sales reps from its hospitals

Reform Update: Ascension Health bars Genentech sales reps from its hospitals

By Bob Herman  |  October 02, 2014

Pharmaceutical giant Genentech has come under a maelstrom of criticism from hospitals for its decision to change its distribution methods for three widely used cancer drugs, and now the nation's largest not-for-profit health system is responding with a bold message.

Genentech's distribution change for cancer drugs upsets hospitals

By Bob Herman  |  September 30, 2014

Drugmaker Genentech is changing the way it ships three high-profile cancer drugs to hospitals, which are concerned that the new process will grossly inflate their already high costs and potentially affect patient care. Genentech contends the change is designed to ensure patient safety and access to...

Google's health startup forges venture with AbbVie

By Associated Press  |  September 03, 2014

Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.

HHS fights back to keep expanded 340B drug discounts

HHS fights back to keep expanded 340B drug discounts

By Jaimy Lee  |  June 12, 2014

The drug industry scored a victory last month against the Obama administration's plans to give hospitals millions of dollars in discounts through the 340B program on orphan drugs. But HHS is sticking to its position that the Patient Protection and Affordable Care Act promises breaks on the...

Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.